COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03814447
Recruitment Status : Recruiting
First Posted : January 24, 2019
Last Update Posted : March 18, 2020
Hrain Biotechnology Co., Ltd.
Information provided by (Responsible Party):
Zhao Hui, Shanghai 6th People's Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2022